- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
11 result(s) found for: Effervescent tablets.
Displaying page 1 of 1.
EudraCT Number: 2007-006117-16 | Sponsor Protocol Number: Puranik 07-03/23 | Start Date*: 2008-07-31 |
Sponsor Name:Betsi Cadwaladr University Health Board | ||
Full Title: A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy ... | ||
Medical condition: post-tonsillectomy pain | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001484-12 | Sponsor Protocol Number: BUL-1/EEA | Start Date*: 2015-09-22 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathol... | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016692-29 | Sponsor Protocol Number: BUU-2/EEA | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspen... | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001485-99 | Sponsor Protocol Number: BUL-2/EER | Start Date*: 2015-12-08 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mai... | |||||||||||||
Medical condition: Maintenance of remission in eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006837-28 | Sponsor Protocol Number: PML_DOC_0804 | Start Date*: 2008-12-08 |
Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine | ||
Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N-acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat... | ||
Medical condition: Chronic Obstructive Pulmonary Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003946-13 | Sponsor Protocol Number: PML_NAC_01 | Start Date*: 2007-09-05 |
Sponsor Name:University Hospital Antwerp; Department Respiratory Medicine | ||
Full Title: Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N acetylcysteine on small airways and on inflammation and oxidative stress in COPD pat... | ||
Medical condition: Chronic Obstructive Pulmonary Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004466-14 | Sponsor Protocol Number: RH01361 | Start Date*: 2011-10-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Consumer Healthcare | |||||||||||||
Full Title: Effects of two doses of a common cold treatment on cognitive function | |||||||||||||
Medical condition: Common cold | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022857-41 | Sponsor Protocol Number: C6930943 | Start Date*: 2010-12-14 | |||||||||||
Sponsor Name:GlaxoSmithKline Consumer Healthcare | |||||||||||||
Full Title: Effects of a common cold treatment on cognitive function | |||||||||||||
Medical condition: Common cold | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003441-16 | Sponsor Protocol Number: ML20570 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:N.V. Roche S.A. | |||||||||||||
Full Title: OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTA... | |||||||||||||
Medical condition: Metastasic bone pain in patients with breast cancer and bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004112-51 | Sponsor Protocol Number: V1512-2PD01 | Start Date*: 2006-11-14 | |||||||||||
Sponsor Name:VERNALIS DEVELOPMENT LIMITED | |||||||||||||
Full Title: A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s ... | |||||||||||||
Medical condition: Parkinson s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000564-14 | Sponsor Protocol Number: PIPF-023 | Start Date*: 2013-06-18 | |||||||||||
Sponsor Name:InterMune International AG. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenid... | |||||||||||||
Medical condition: Patients with Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
